Oestreicher M K, Desmeules J, Piguet V, Allaz A F, Dayer P
Division de pharmacologie clinique, Hôpital cantonal universitaire de Genève.
Schweiz Med Wochenschr. 1998 Feb 7;128(6):212-5.
Administration of NMDA antagonists leads to attenuation or disappearance of some symptoms of central sensitization, such as secondary hyperalgesia. However, the side effects of NMDA antagonists to a large extent counterbalance the expected benefits, thus preventing wide or prolonged use. Dextromethorphan and its metabolite dextrophan, on the other hand, are established and safe drugs. Experimentally they both antagonize the NMDA receptor. This study evaluates the effects of dextromethorphan and its metabolite in pain models using electrical stimulation for testing the antinociceptive effect and capsaicin-induced hyperalgesia. Dextromethorphan shows clear antinociceptive as well as neuromodulary effects, both depending heavily on the cytochrome P450 2D6 phenotype (CYP2D6).
给予NMDA拮抗剂会导致中枢敏化的一些症状减轻或消失,如继发性痛觉过敏。然而,NMDA拮抗剂的副作用在很大程度上抵消了预期的益处,从而阻碍了其广泛或长期使用。另一方面,右美沙芬及其代谢产物右啡烷是已确定的安全药物。实验表明,它们都能拮抗NMDA受体。本研究使用电刺激来测试镇痛作用和辣椒素诱导的痛觉过敏,评估右美沙芬及其代谢产物在疼痛模型中的作用。右美沙芬显示出明显的镇痛和神经调节作用,这两者都严重依赖于细胞色素P450 2D6表型(CYP2D6)。